Caris Life Sciences, Inc. (CAI) Total Return Calculator with Dividends Reinvested

Caris Life Sciences, Inc.

Popular:

The total return for Caris Life Sciences, Inc. (CAI) stock is -29.07% over the past 12 months. So far it's down 26.39% this year. The 5-year total return is -29.07%, meaning $10,000 invested in CAI stock 5 years ago would be worth $7,093 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in CAI 1 year ago, it would be worth $7,093 today — you'd have lost $2,907.

With Dividends Reinvested$7,093-29.07%

Price Only (No DRIP)$7,093-29.07%

Period2025-06-18 → 2026-03-04

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in CAI

1Y$7,093-$2,907 (-29.1%)-29.1% CAGR

3Y$7,093-$2,907 (-29.1%)-10.8% CAGR

5Y$7,093-$2,907 (-29.1%)-6.6% CAGR

10Y$7,093-$2,907 (-29.1%)-3.4% CAGR

15Y$7,093-$2,907 (-29.1%)-2.3% CAGR

20Y$7,093-$2,907 (-29.1%)-1.7% CAGR

30Y$7,093-$2,907 (-29.1%)-1.1% CAGR

Caris Life Sciences, Inc. did not pay dividends during this period. Total return = price return.

Loading CAI total return...

As of 2026-03-05

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	-26.39%	—	-26.39%	—	$7,361
1Y	-29.07%	-29.07%	-29.07%	—	$7,093
3Y	-29.07%	-10.82%	-29.07%	—	$7,093
5Y	-29.07%	-6.64%	-29.07%	—	$7,093
10Y	-29.07%	-3.38%	-29.07%	—	$7,093
15Y	-29.07%	-2.26%	-29.07%	—	$7,093
20Y	-29.07%	-1.70%	-29.07%	—	$7,093
30Y	-29.07%	-1.14%	-29.07%	—	$7,093

Risk & Highlights

Best Year-3.64%2025

Worst Year-3.64%2025

Max Drawdown-55.11%2025-08-22 → 2026-02-23

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	-25.35%	-25.35%	—	+0.41%	-25.8pp
2025	-3.64%	-3.64%	—	+16.64%	-20.3pp

CAI underperformed the S&P 500 by 45.75pp over the past year (-29.07% vs +16.68%).

Loading summary...

CAI Peers' Total Return

Biotechnology · Top 11 by market cap

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
CAICaris Life Sciences, Inc.	$33.2B	-6.5%	-26.4%	-29.1%	—	-29.1%	-29.1%	-29.1%
VRTXVertex Pharmaceuticals Incorporated	$121.4B	+4.2%	+5.7%	-2.8%	—	+63.9%	+125.4%	+425.4%
REGNRegeneron Pharmaceuticals, Inc.	$108.4B	+2.7%	+1.6%	+15.1%	+0.5pp	+1.5%	+71.6%	+94.0%
PHGEBiomX Inc.	$82.8B	+38.2%	+194.4%	-48.8%	—	-93.2%	-99.5%	-99.7%
ARGXargenx SE	$46.4B	-8.6%	-10.8%	+17.8%	—	+119.3%	+158.7%	+3159.0%
ALNYAlnylam Pharmaceuticals, Inc.	$43.3B	-1.2%	-18.2%	+31.3%	—	+63.9%	+128.3%	+444.7%
RPRXRoyalty Pharma plc	$26.8B	+7.6%	+22.7%	+43.1%	+2.7pp	+42.2%	+21.0%	+16.7%
BNTXBioNTech SE	$26.0B	-1.6%	+7.4%	-9.6%	—	-21.1%	+10.1%	+643.8%
MRNAModerna, Inc.	$22.6B	+41.4%	+87.3%	+64.2%	—	-59.9%	-56.3%	+210.8%
ROIVRoivant Sciences Ltd.	$21.4B	+39.6%	+34.6%	+175.9%	—	+275.1%	+197.6%	+183.8%
UTHRUnited Therapeutics Corporation	$21.4B	+2.4%	-1.3%	+57.6%	—	+97.6%	+198.3%	+271.7%

Compare:CAI vs VRTX CAI vs REGN CAI vs PHGE CAI vs VRTX vs REGN

About CAI Dividend Returns

Caris Life Sciences, Inc. (CAI) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of CAI over the past year?

Caris Life Sciences, Inc. (CAI) delivered a return of -29.07% over the past year. Since CAI does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in CAI be worth today?

A $10,000 investment in Caris Life Sciences, Inc. one year ago would be worth $7,093 today, representing a loss of $2,907.

Q3Does CAI pay dividends?

Caris Life Sciences, Inc. (CAI) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For CAI, the total return equals the price-only return.

Q4Did CAI beat the S&P 500?

No, Caris Life Sciences, Inc. (CAI) underperformed the S&P 500 by 45.75 percentage points over the past year. CAI delivered a total return of -29.07%, compared to the S&P 500's 16.68%. This means a passive S&P 500 index fund outperformed CAI by 45.75pp during this period.

Q5What is CAI's worst drawdown?

Caris Life Sciences, Inc. (CAI) experienced a maximum drawdown of -55.11% over the past year, declining from its peak on 2025-08-22 to its trough on 2026-02-23. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is CAI's long-term total return over 10, 20, or 30 years?

Caris Life Sciences, Inc. (CAI) has delivered strong long-term returns with dividends reinvested. Over 10 years, the total return is -29.1% (-3.4% CAGR) — $10,000 would have grown to $7,093. Over 20 years: -29.1% total return (-1.7% CAGR) — $10,000 → $7,093. Over 30 years: -29.1% total return (-1.1% CAGR) — $10,000 → $7,093. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was CAI's best and worst year?

Caris Life Sciences, Inc.'s best calendar year was 2025 with a total return of -3.6%. Its worst year was 2025 with a total return of -3.6%. This range shows the volatility investors should expect — the difference between the best and worst year is 0.0 percentage points.